- Conditions
- COPD (Chronic Obstructive Pulmonary Disease)
- Interventions
- umeclidinium 62.5 µg and vilanterol 25 µg, Revefenacin 175 µg, Formoterol 20 µg, Placebo ( Revefenacin and Formoterol ), Placebo DPI
- Drug
- Lead sponsor
- University of Tennessee Graduate School of Medicine
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- TD-4208, Placebo
- Drug
- Lead sponsor
- Mylan Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 611 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Easley, South Carolina
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- TD-4208, Placebo
- Drug
- Lead sponsor
- Mylan Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 619 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Cardiac Repolarization in Healthy Subjects
- Interventions
- TD-4208 175 mcg, TD-4208 700 mcg, Placebo for TD-4208, Moxifloxacin 400 mg
- Drug
- Lead sponsor
- Mylan Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Chronic Obstructive Pulmonary Disease, COPD, Low Peak Inspiratory Flow Rate (PIFR)
- Interventions
- Revefenacin, Spiriva Handihaler®, Placebo for Revefenacin, Placebo for Spiriva Handihaler®
- Drug · Combination Product
- Lead sponsor
- Mylan Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Rock Hill, South Carolina
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Revefenacin, Tiotropium, Revefenacin Placebo, Tiotropium Placebo
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 404 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 76
- States / cities
- Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- TD-4208, Tiotropium
- Drug
- Lead sponsor
- Mylan Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,060 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Easley, South Carolina
- Conditions
- Chronic Obstructive Pulmonary Disease, COPD
- Interventions
- TD-4208, Placebo
- Drug
- Lead sponsor
- Mylan Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Revefenacin, Placebo, Formoterol
- Drug
- Lead sponsor
- Mylan Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 12
- States / cities
- Miami, Florida • Orlando, Florida • Sarasota, Florida + 9 more
- Conditions
- COPD
- Interventions
- TD-4208, Placebo
- Drug
- Lead sponsor
- Mylan Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Greenville, South Carolina
- Conditions
- COPD Exacerbation
- Interventions
- Revefenacin, formoterol fumarate, Placebo (Sterile Normal Saline), Albuterol sulfate, Ipratropium Bromide
- Drug · Other
- Lead sponsor
- University of Tennessee Graduate School of Medicine
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee